Skip to main content
Fig. 2 | Journal of Pharmaceutical Policy and Practice

Fig. 2

From: Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997

Fig. 2

Estimated regression coefficients. The imminence of generic entry negatively impacts the chances of a new indication being developed for an NME. Holding the effect of age constant, generic entry’s influence upon reducing the chances of a new indication addition is strongest when generic has already occurred and weakest when generic entry is still 5–10 years into the future

Back to article page